Jefferson researchers have found an effective treatment for an under-diagnosed condition that can cause symptoms similar to that of a heart attack.
Not much is known about coronary slow flow, a condition in which arteries fill with blood more slowly than normal – even without fatty plaque deposits. The condition causes severe chest pain.
- RELATED STORIES
- FDA approves cardiovascular health claim for certain cooking oils
- Penn study finds that black patients are much more likely to die of sudden cardiac death
- 'Broken heart syndrome' is a real thing – and it can quickly turn deadly, study says
Researchers have not determined its cause, nor do they understand why 80 percent of diagnosed patients experience additional episodes of chest pain. Though the condition appears on angiograms of the heart, many cardiologists aren't familiar with the condition and therefore miss diagnosing it, according to Jefferson researchers.
But despite all the unknowns surrounding coronary slow flow, Jefferson researchers have developed an effective treatment. Their findings were published last Saturday in the Journal of Invasive Cardiology.
"Here we've shown that once you do recognize it, the condition can be treated with an existing and safe medical intervention that reverses the problem," senior author Dr. Michael Savage said in a statement.
Coronary slow flow can be treated with nicardipine, a drug that is used to treat a no-reflow phenomenon caused by microvascular spasm during coronary angioplasty procedures.
Jefferson researchers analyzed the data and outcomes of 30 patients who received a nicardipine injection during cardiac catheterization. They found 49 total blood vessels experiencing slow blood flow. After the injection, each blood vessel had a normal blood flow.
"It is a simple intervention that takes only a few seconds to administer and helps diagnose the condition and treat it at the same time," Savage said.
The drug appears to reverse coronary slow flow in the short term, but additional research is needed to determine whether results are permanent.
Follow John & PhillyVoice on Twitter: @WriterJohnKopp | @thePhillyVoice
Like us on Facebook: PhillyVoice
Add John's RSS feed to your feed reader
Have a news tip? Let us know.